Suppr超能文献

新型冠状病毒肺炎疫苗接种后新发和复发肝病:系统评价。

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review.

机构信息

Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Rashdiah Street, P. O. Box 12944, Al-Ahsa, 31982, Saudi Arabia.

Research Center, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.

出版信息

BMC Gastroenterol. 2022 Oct 13;22(1):433. doi: 10.1186/s12876-022-02507-3.

Abstract

BACKGROUND

Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines.

OBJECTIVES

To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination.

METHODS

For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction.

RESULTS

Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy.

CONCLUSION

Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.

摘要

背景

COVID-19 疫苗接种后肝脏疾病极为罕见,但可能会发生。越来越多的证据表明,门静脉血栓形成、自身免疫性肝炎、肝酶升高和肝损伤等可能是 COVID-19 疫苗的潜在后果。

目的

描述 COVID-19 疫苗接种后新发和复发性肝病的系统评价结果。

方法

本系统评价按照 PRISMA 指南,通过 Proquest、Medline、Embase、PubMed、CINAHL、Wiley 在线图书馆、Scopus 和 Nature 搜索 COVID-19 疫苗接种后新发或复发性肝病发生率的研究,检索时间为 2020 年 12 月 1 日至 2022 年 7 月 31 日,仅限英文文献。

结果

从 118 篇文章中纳入了本系统评价的定性综合分析的 275 例病例。COVID-19 疫苗接种后最常见的病理表现是自身免疫性肝炎(138 例),其次是门静脉血栓形成(52 例)、肝酶升高(26 例)和肝损伤(21 例)。其他病例包括脾静脉血栓形成、肝急性细胞排斥反应、黄疸、肝肿大、急性肝衰竭和肝卟啉症。在包括的病例中,任何病例都有急性肝衰竭(n=4,50%)、门静脉血栓形成(n=25,48.1%)、脾静脉血栓形成(n=6,42.8%)、黄疸(n=1,12.5%)、肝酶升高(n=2,7.7%)和自身免疫性肝炎(n=3,2.2%)患者死亡报道。大多数患者容易治疗,没有任何严重并发症,康复后无需长期肝治疗。

结论

COVID-19 疫苗接种后肝脏疾病的报告证据不应阻止针对这一全球大流行的疫苗接种。与已接种的数亿剂疫苗相比,报告的病例数量相对较少,COVID-19 疫苗接种的保护益处远远超过风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e4e/9563568/581d049eec4b/12876_2022_2507_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验